Page last updated: 2024-11-08

adelmidrol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

adelmidrol: Antiinflammatory Agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID176874
CHEMBL ID2105967
SCHEMBL ID636771
MeSH IDM0550492

Synonyms (31)

Synonym
nsc-27132
nsc27132
1675-66-7
adelmidrol
n,n'-bis(2-hydroxyethyl)nonanediamide
nsc 27132
unii-1buc3685qu
adelmidrol [inn]
CHEMBL2105967
1buc3685qu ,
S6551
adelmidrol [who-dd]
CCG-213729
SCHEMBL636771
CS-4543
nonanediamide, n,n'-bis(2-hydroxyethyl)-
HY-B1026
AB01563184_01
DTXSID10168302
AKOS028111150
EX-A1239
SR-01000944279-1
sr-01000944279
BCP24910
Q15633949
n1,n9-bis(2-hydroxyethyl)nonanediamide
FT-0778179
C73226
AS-56183
adelmitrol
BAA67566

Research Excerpts

Overview

Adelmidrol is a semisynthetic derivative of azelaic acid. It is an analogue of the anti-inflammatory compound palmitoylethanolamide (PEA)

ExcerptReferenceRelevance
"Adelmidrol is a semisynthetic derivative of azelaic acid and analogue of the anti-inflammatory compound palmitoylethanolamide (PEA). "( Inhibitory effect of topical adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitis.
Brazis, P; Cerrato, S; Della Valle, MF; Miolo, A; Puigdemont, A, 2012
)
2.11

Treatment

Adelmidrol treatment, moreover, reduced nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release.

ExcerptReferenceRelevance
"Adelmidrol treatment, moreover, reduced nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release; and the incidence of nitrotyrosine and poly(ADP)ribose in the colon."( Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease.
Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016
)
2.6
"Treatment with adelmidrol decreased diarrhea, body weight loss, and myeloperoxidase activity."( Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease.
Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016
)
2.22

Compound-Compound Interactions

The aim of this study was to evaluate the effect of adelmidrol, a synthetic palmitoylethanolamide analogue, combined with hyaluronic acid on pain severity and modulation of the inflammatory response in a rat model of monosodium iodoacetate-induced osteoarthritis.

ExcerptReferenceRelevance
" The aim of this study was to evaluate the effect of adelmidrol, a synthetic palmitoylethanolamide analogue, combined with hyaluronic acid on pain severity and modulation of the inflammatory response in a rat model of monosodium iodoacetate (MIA)-induced osteoarthritis."( Adelmidrol, in combination with hyaluronic acid, displays increased anti-inflammatory and analgesic effects against monosodium iodoacetate-induced osteoarthritis in rats.
Britti, D; Cordaro, M; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Impellizzeri, D; Morittu, VM, 2016
)
2.13
" Rats subjected to OA were treated by intra-articular injection of adelmidrol in combination with sodium hyaluronate at different doses and time points after MIA induction."( Adelmidrol, in combination with hyaluronic acid, displays increased anti-inflammatory and analgesic effects against monosodium iodoacetate-induced osteoarthritis in rats.
Britti, D; Cordaro, M; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Impellizzeri, D; Morittu, VM, 2016
)
2.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's9 (64.29)24.3611
2020's4 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.66 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews1 (7.14%)6.00%
Case Studies1 (7.14%)4.05%
Observational1 (7.14%)0.25%
Other10 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]